Zogenix Obtains $51,000,000 Series B Funding

  • Feed Type
  • Date
    9/23/2009
  • Company Name
    Zogenix
  • Mailing Address
    12671 High Bluff Drive San Diego, CA 92130
  • Company Description
    Zogenix is a specialty pharmaceutical company whose goal is to uniquely enhance and differentiate medicines by incorporating innovative technologies in an effort to relieve suffering in people with CNS and pain disorders. Founded in 2006, the company currently has two proprietary product candidates in late-stage development. Our lead product candidate, SUMAVEL™ DOSEPRO™ (sumatriptan injection) needle-free delivery system, is a drug-device combination that enables needle-free delivery of subcutaneous sumatriptan – the fastest acting migraine medicine – for the treatment of migraine and cluster headache. Our second product candidate, ZX002, is a novel, oral controlled-release formulation of hydrocodone for the treatment of chronic pain.
  • Website
    http://www.zogenix.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $51,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The capital will be used to finance the launch of SUMAVEL DosePro (sumatriptan injection) needle-free delivery system, the company’s first product, which recently received FDA approval.
  • M&A Terms
  • Venture Investor
    Clarus Ventures
  • Venture Investor
    Domain Associates
  • Venture Investor
    Scale Venture Partners
  • Venture Investor
    Thomas, McNerny & Partners
  • Venture Investor
    Abingworth Management Inc
  • Venture Investor
    Oxford Finance Corporation

By posting a comment, you agree to our terms and conditions.